A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia

Blood

Volumn 87, Issue 8, 1996, Pages 3143-3150

  Welte, Karl ^a   Reiter, Alfred ^b   Mempel, Kerstin ^b   Pfetsch, Marina ^b   Schwab, Gisela ^b   Schrappe, Martin ^b   Riehm, Hansjörg ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER IMMUNOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SCREENING; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; NEUTROPENIA; PETECHIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VASCULITIS;

6-MERCAPTOPURINE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FEVER; FILGRASTIM; GASTROINTESTINAL DISEASES; GERMANY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HUMANS; IFOSFAMIDE; INFANT; INFECTION CONTROL; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LIFE TABLES; MALE; METHOTREXATE; NEUTROPENIA; PREDNISOLONE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RISK; SURVIVAL ANALYSIS; THIOGUANINE; VINCRISTINE; VINDESINE;

EID: 0029978292     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.8.3143.bloodjournal8783143     Document Type: Article

References (29)

1. Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Welte K, Gadner H, Riehm H: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122, 1994
2. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donelly M, Dalton V, Cohen HJ, Sallan SE: Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Faber Cancer Institute/ Children's hospital acute lymphoblastic leukemia consortium protocol 85-01 J Clin Oncol 12:740, 1994
3. Rivera GK, Pinkel D, Simone JV, Hancock ML, Crist WM: Treatment of acute lymphoblastic leukemia. N Engl J Med 329:1289, 1993
4. Riehm H, Feickert HJ, Schrappe M, Henze G, Schellong G: Therapy results in five ALL-BFM studies since 1970. Implications of risk factors for prognosis. Haematol Blood Transfus 30:139, 1987
5. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch M, Mirro JJ, Ochs JS, Look AT, Williams DL, Murphy SB, Dahl GV, Kalwinsky DK, Evans WE, Kun LE, Simone JV, Crist WM: Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337:61, 1991
6. Chessels JM, Bailey CC, Richards S: The UK protocol for childhood ALL: 1985-1990. Leuk 6:157, 1992 (suppl 2)
7. Tubergen DG, Gilchrist GS, O'Brien RTO, Coccia PF, Sather HN, Waskerwitz MJ, Hammond GD: Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features. A Childrens Cancer Group phase III trial. J Clin Oncol 11:527, 1993
8. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, Ludwig R, Ritter J, Stollmann B, Henze G: Die corticosteroid-abhängige dezimierung der leukämiezellzahl im blut als prognosefaktor bei der akuten lymphoblastischen leukämie im kindesalter (Therapiestudie ALL-BFM 83). Klin Pädiat 199:151, 1986
9. Crist W, Carroll A, Shuster J, Jackson J, Head D, Borowitz M, Behm F, Link M, Steuber P, Ragab A, Hirt A, Brock B, Land V, Pullen J: Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Clinical cytogenetic characteristics and treatment outcome. A pediatric oncology group study. Blood 76:489, 1990
10. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong C, Grous J, Yagoda A, Fain K, Moore MAS, Clarkson B, Oettgen H, Alton K, Weite K, Souza L: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414, 1988
11. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishar W, Yahanda A, Vincent M, Stewart M, Glaspy J: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 315:164, 1991
12. Trillet-Lenoir V, Green J, Mangegold C: Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29:319, 1993
13. Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T, Omine M, Oh H, Nomura T, Sakai Y, Hirano M, Yokomaku S, Nakayama S, Yoshida Y, Miura AB, Morishima Y, Dohy H, Niho Y, Hamajima N, Takaku F: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323:871, 1990
14. Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, Kane K, Bentley J, Crowther D: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430, 1992
15. Scherrer R, Geissler K, Kyrle PA, Gisslinger H, Jäger U, Bettelheim P, Laczika K, Locker G, Scholten C, Sillaber C, Schwarzinger I, Thalhammer F, Lechner K: Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL). Ann Hematol 66:283, 1993
16. Ottmann OG, Hoelzer D, Gracien E, Ganser A, Reutzel R, Lipp T, Busch FW, Schwonzen M, Heil G, Wandt H, Koch P, Kolbe K, Heyll A, Bentz M, Peter S, Diedrich H, Dethling J, Meyer P, Nowrousian MR, Löffler B, Weiss A, Kneba M, Föller A, Graf M, Hecht T: Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: A randomized phase III trial. Blood 86:444, 1995
17. Stahel RA, Lorenz MJ, Cerny T, Pichert G, Honegger H, Jacky E, Fey M, Platzer E: A randomized study of recombinant human granulocyte colony stimulating factor (Filgrastim) after high dose chemotherapy and autologous bone marrow transplantation for high risk lymphoid malignancies. J Clin Oncol 12:1931, 1994
18. Schmitz N, Dreger P, Zander A, Ehninger G, Wandt H, Fauser AA, Kolb HJ, Zumsprekel A, Martin A, Hecht T: A randomized, controlled, multicentre study of recombinant human granulocyte colony stimulating factor (r-metHuG-CSF, Filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation (ABMT). Bone Marrow Transplant 15:261, 1995
19. Housholder SE, Rackoff WR, Goldman J, Breitfeld PP: A case-control retrospective study of the efficacy of granulocyte-colony-stimulating factor in children with neuroblastoma. Am J Ped Hematol Oncol 16:132, 1994
20. Stute N, Santana VM, Rodman JH, Schell MJ, Ihle JN, Evans WE: Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 79:2849, 1992
21. Bonilla MA, Dale D, Zeidler C, Last L, Reiter A, Ruggeiro M, Davis M, Koci B, Hammond W, Gillio A, Welte K: Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Hematol 88:723, 1994
22. Siegal S, Castellan NJ: The median test, in Siegal S, Castellan NJ (eds): Nonparametric Statistics for the Behavioral Sciences. (ed 2). New York, NY, McGraw-Hill, 1988, p 124
23. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
24. Calderwood S, Romeyer F, Blanchette V, Chan H, Doyle J, Greenberg M, Lorenzana A, Malkin D, Saunders F, Weitzman S, Zipursky A, Freedman MH: Concurrent rhGM-CSF does not offset myelosuppression from intensive chemotherapy: Randomized placebo-controlled study in childhood acute lymphoblastic leukemia. Am J Hematol 47:27, 1994
25. Bronchud M: Can hematopoietic growth factors be used to improve the success of cytotoxic chemotherapy. Anticancer Drugs 4:127, 1993
26. Tsuchiya H, Adachi N, Asou N, Takatsuki K, Matsuda I, Kawano F, Murakami T, Mizutani S, Watanabe N: Responses to granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage CSF in Ph1-positive acute lymphoblastic leukemia with myeloid surface markers. Blood 77:411, 1991
27. Ohyashiki JH, Ohyashiki K, Miyauchi J, Fujieda H, Tauchi T, Saito M, Nakazawa S, Kimura N, Clark SC, Toyama K: Immuno-genotypes and clonal culture analysis in B-precursor acute lymphoblastic leukemia. Leukemia 6:240, 1992
28. Ohno R, Hiraoka A, Tanimoto M, Asou N, Kuriyama K, Kobayashi T, Yoshida M, Teshima H, Saito H, Fujimoto K: No increase of leukemia relapse in newly diagnosed patients with acute myeloid leukemia who received granulocyte colony-stimulating factor for life-threatening infection during remission induction and consolidation therapy. Blood 81:561, 1993
29. Tafuri A, Andreeff M: Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4:826, 1990